Ben Gil Price, Director at Sarepta Therapeutics, Inc. (SRPT), bought 500 shares at $31.18 ($16K) on 2013-08-19, disclosed to the SEC on 2013-08-20.
Open-market purchase of $16k SRPT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| AVII | BUY | 2012-03-15 | $39K | — | Filing → |
| AVII | BUY | 2011-04-06 | $30K | — | Filing → |
| AVII | BUY | 2010-08-16 | $8K | — | Filing → |